A citation-based method for searching scientific literature

Lénaïg Mescam-Mancini, Sylvie Lantuéjoul, Denis Moro-Sibilot, Isabelle Rouquette, Pierre-Jean Souquet, Clarisse Audigier-Valette, Jean-Christophe Sabourin, Chantal Decroisette, Linda Sakhri, Elisabeth Brambilla, Anne McLeer-Florin. Lung Cancer 2014
Times Cited: 81







List of co-cited articles
734 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
979
71

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
62

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Lynette M Sholl, Heather Sun, Mohit Butaney, Chengsheng Zhang, Charles Lee, Pasi A Jänne, Scott J Rodig. Am J Surg Pathol 2013
114
59

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.
Akihiko Yoshida, Koji Tsuta, Susumu Wakai, Yasuhito Arai, Hisao Asamura, Tatsuhiro Shibata, Koh Furuta, Takashi Kohno, Ryoji Kushima. Mod Pathol 2014
89
50

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
834
49

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Victoria M Rimkunas, Katherine E Crosby, Daiqiang Li, Yerong Hu, Meghan E Kelly, Ting-Lei Gu, Jennifer S Mack, Matthew R Silver, Xinmin Zhou, Herbert Haack. Clin Cancer Res 2012
191
45

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Kurtis D Davies, Anh T Le, Mariana F Theodoro, Margaret C Skokan, Dara L Aisner, Eamon M Berge, Luigi M Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli,[...]. Clin Cancer Res 2012
275
44

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
43

ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.
Arne Warth, Thomas Muley, Hendrik Dienemann, Benjamin Goeppert, Albrecht Stenzinger, Philipp A Schnabel, Peter Schirmacher, Roland Penzel, Wilko Weichert. Histopathology 2014
72
45

Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
Yoon Jin Cha, Jae Seok Lee, Hye Ryun Kim, Sun Min Lim, Byoung Chul Cho, Chang Young Lee, Hyo Sup Shim. PLoS One 2014
58
56

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
38

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild,[...]. J Clin Oncol 2015
227
38

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Akihiko Yoshida, Takashi Kohno, Koji Tsuta, Susumu Wakai, Yasuhito Arai, Yoko Shimada, Hisao Asamura, Koh Furuta, Tatsuhiro Shibata, Hitoshi Tsuda. Am J Surg Pathol 2013
110
34

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
H R Kim, S M Lim, H J Kim, S K Hwang, J K Park, E Shin, M K Bae, S-H I Ou, J Wang, S S Jewell,[...]. Ann Oncol 2013
74
35

Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
Heounjeong Go, Dong-Wan Kim, Donghyun Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo, Yung-Jue Bang, Doo Hyun Chung. J Thorac Oncol 2013
50
52

ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.
Theresa A Boyle, Katsuhiro Masago, Kim E Ellison, Yasushi Yatabe, Fred R Hirsch. Clin Lung Cancer 2015
38
68

Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
Ling Shan, Fang Lian, Lei Guo, Tian Qiu, Yun Ling, Jianming Ying, Dongmei Lin. PLoS One 2015
54
44

Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Toni-Maree Rogers, Prudence A Russell, Gavin Wright, Zoe Wainer, Jia-Min Pang, Leigh A Henricksen, Shalini Singh, Stacey Stanislaw, James Grille, Esteban Roberts,[...]. J Thorac Oncol 2015
55
41

Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
Seung Eun Lee, Boram Lee, Mineui Hong, Ji-Young Song, Kyungsoo Jung, Maruja E Lira, Mao Mao, Joungho Han, Jhingook Kim, Yoon-La Choi. Mod Pathol 2015
74
29

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Lukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando López-Ríos, Antonio Marchetti, Büge Öz, Patrick Pauwels,[...]. Virchows Arch 2016
113
24

Molecular pathways: ROS1 fusion proteins in cancer.
Kurtis D Davies, Robert C Doebele. Clin Cancer Res 2013
193
23

Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.
Yen-Fu Chen, Min-Shu Hsieh, Shang-Gin Wu, Yih-Leong Chang, Jin-Yuan Shih, Yi-Nan Liu, Meng-Feng Tsai, Tzu-Hsiu Tsai, Chong-Jen Yu, James Chih-Hsin Yang,[...]. J Thorac Oncol 2014
51
37

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
22

ROS1 fusions in Chinese patients with non-small-cell lung cancer.
W Cai, X Li, C Su, L Fan, L Zheng, K Fei, C Zhou, C Manegold, G Schmid-Bindert. Ann Oncol 2013
63
28

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
20

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
19

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
19

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Justin F Gainor, Alice T Shaw. Oncologist 2013
204
19

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.
Matthias Scheffler, Anne Schultheis, Cristina Teixido, Sebastian Michels, Daniela Morales-Espinosa, Santiago Viteri, Wolfgang Hartmann, Sabine Merkelbach-Bruse, Rieke Fischer, Hans-Ulrich Schildhaus,[...]. Oncotarget 2015
59
27

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Christina I Selinger, Bob T Li, Nick Pavlakis, Matthew Links, Anthony J Gill, Adrian Lee, Stephen Clarke, Thang N Tran, Trina Lum, Po Y Yip,[...]. Histopathology 2017
32
50

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Neal I Lindeman, Philip T Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire,[...]. J Thorac Oncol 2013
538
18

Expression and rearrangement of the ROS1 gene in human glioblastoma cells.
C Birchmeier, S Sharma, M Wigler. Proc Natl Acad Sci U S A 1987
149
18

Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
Lynette M Sholl, Stanislawa Weremowicz, Stacy W Gray, Kwok-Kin Wong, Lucian R Chirieac, Neal I Lindeman, Jason L Hornick. J Thorac Oncol 2013
117
18

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
17

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Yunjian Pan, Yang Zhang, Yuan Li, Haichuan Hu, Lei Wang, Hang Li, Rui Wang, Ting Ye, Xiaoyang Luo, Yiliang Zhang,[...]. Lung Cancer 2014
140
17

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.
Esther Conde, Ana Suárez-Gauthier, Amparo Benito, Pilar Garrido, Rosario García-Campelo, Michele Biscuola, Luis Paz-Ares, David Hardisson, Javier de Castro, M Carmen Camacho,[...]. PLoS One 2014
50
28

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Yoshiyuki Suehara, Maria Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, Yuki Kimura, Alexander Drilon, Udayan Guha, Valerie Rusch,[...]. Clin Cancer Res 2012
125
17

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Philipp Jurmeister, Dido Lenze, Erika Berg, Stefanie Mende, Frank Schäper, Udo Kellner, Hermann Herbst, Christine Sers, Jan Budczies, Manfred Dietel,[...]. Lung Cancer 2015
37
37

Anchored multiplex PCR for targeted next-generation sequencing.
Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova, Yi Cao, Divya Panditi, Kerry D Lynch, Juxiang Chen, Hayley E Robinson, Hyo Sup Shim, Juliann Chmielecki,[...]. Nat Med 2014
471
17

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Marcel Wiesweg, Wilfried E E Eberhardt, Henning Reis, Saskia Ting, Nikoleta Savvidou, Charlotte Skiba, Thomas Herold, Daniel C Christoph, Johannes Meiler, Karl Worm,[...]. J Thorac Oncol 2017
40
35

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
Mari Mino-Kenudson, Lucian R Chirieac, Kenny Law, Jason L Hornick, Neal Lindeman, Eugene J Mark, David W Cohen, Bruce E Johnson, Pasi A Jänne, A John Iafrate,[...]. Clin Cancer Res 2010
338
16

Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.
Ting-Lei Gu, Xiaxing Deng, Feizhou Huang, Meghan Tucker, Katherine Crosby, Victoria Rimkunas, Yi Wang, Gang Deng, Lei Zhu, Zhiping Tan,[...]. PLoS One 2011
208
16

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
Scott J Rodig, Mari Mino-Kenudson, Sanja Dacic, Beow Y Yeap, Alice Shaw, Justine A Barletta, Hannah Stubbs, Kenny Law, Neal Lindeman, Eugene Mark,[...]. Clin Cancer Res 2009
480
16

KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
537
16

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
Alexander Drilon, Lu Wang, Adnan Hasanovic, Yoshiyuki Suehara, Doron Lipson, Phil Stephens, Jeffrey Ross, Vincent Miller, Michelle Ginsberg, Maureen F Zakowski,[...]. Cancer Discov 2013
336
16

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
318
16

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
16


International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
William D Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G Nicholson, Kim R Geisinger, Yasushi Yatabe, David G Beer, Charles A Powell, Gregory J Riely, Paul E Van Schil,[...]. J Thorac Oncol 2011
14

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.